Targeting a

Fuller Life

Rain Therapeutics researches, develops and translates innovative targeted cancer therapies for patients

Rain Therapeutics is focused on patients struggling with difficult cancers, and we help provide them hope to get their lives back.

Scientific programs

Rain’s programs  target oncogenic drivers for which it is able to genetically select patients it believes will most likely benefit.

MilademetaN

Rain’s lead drug candidate, milademetan, is an oral small molecule, inhibitor of mouse double minute 2 (MDM2). It is in clinical development  in patients with liposarcoma and other MDM2 - dependent cancers.

Rad52 Research program

Rain’s RAD52 research program is currently in preclinical development. RAD52 plays a central role in the DNA Damage Response (DDR) pathway.

Resources & Publications

Rain in the News

Rain Therapeutics Announces a Poster Presentation at the 2022 San Antonio Breast Cancer Symposium
November 23, 2022 8:00 AM
NEWARK, Calif., November 23, 2022 (GLOBENEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced a poster presentation at the upcoming 2022 San Antonio Breast Cancer Symposium (SABCS) taking place on December 6-10, 2022 in San Antonio, TX.
Rain Therapeutics to Participate in Piper Sandler’s 34th Annual Healthcare Conference
November 18, 2022 8:00 AM
NEWARK, Calif., November 18, 2022 (GLOBE NEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (“Rain”), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced that it will be participating in Piper Sandler’s 34th Annual Healthcare Conference, being held November 29 – December 1, 2022, in New York.
Rain Therapeutics Announces an Oral Presentation at the Connective Tissue Oncology Society Annual Meeting
November 17, 2022 1:00 PM
NEWARK, Calif., November 17, 2022 (GLOBENEWSWIRE) -- Rain Therapeutics Inc. (NasdaqGS: RAIN), (Rain), a late-stage biotechnology company developing precision oncology therapeutics with a lead product candidate, milademetan, an oral, small molecule inhibitor of the MDM2-p53 complex that reactivates p53, today announced an oral presentation at the Connective Tissue Oncology Society (CTOS) Annual Meeting taking place on November 16-19, 2022 in Vancouver, BC, Canada.